Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5.

Sakr, Elsa; Almeida, Nisha D; Langlois, Marc-Andre; Dasgupta, Kaberi; Mazer, Bruce D

Sakr, Elsa; Almeida, Nisha D; Langlois, Marc-Andre; Dasgupta, Kaberi; Mazer, Bruce D.

Afiliação

Sakr E; Translational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montréal, Québec, Canada.
Almeida ND; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada; Health Technology Assessment Unit, McGill University Health Center, Montréal, Québec, Canada.
Langlois MA; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Dasgupta K; Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada; Center for Outcomes Research and Evaluation, Research Institute of the McGill University Health Center, Montréal, Québec, Canada.
Mazer BD; Translational Research in Respiratory Diseases, Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montréal, Québec, Canada; Department of Pediatrics, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada. Electronic address: bruc

J Allergy Clin Immunol ; 153(3): 874-875, 2024 Mar.

Article em En | MEDLINE | ID: mdl-38159096

Assuntos

Vacinas contra COVID-19; COVID-19; Humanos; COVID-19/prevenção & controle; Anticorpos Antivirais; Anticorpos Neutralizantes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google